Trialbee, a Swedish patient-recruitment outfit, has added AstraZeneca to its client roster, bringing its direct-to-patient technology to the U.K. drugmaker.
Trialbee has added another large pharma to its list of clients, with AstraZeneca following Novo Nordisk in signing up to work with the online trial recruitment specialist. The AstraZeneca deal spans multiple regions, therapeutic areas and phases of clinical trials.
Mayo Clinic and IBM have teamed up to apply cutting-edge technology to the age-old problem of enrolling patients into clinical trials. Starting next year Mayo Clinic will use IBM's supercomputer Watson to automatically match patients to clinical trials.
Global CRO INC Research has teamed up with a trade group of clinical research sites, lending its expertise in an effort to better integrate sponsors, CROs and investigators in the R&D process.
Contract outfit TKL Research has opened a new early-phase-focused clinic in Northern New Jersey, looking to capitalize on demand for Phase I services as it expands its footprint.
With the likes of Pfizer keen for clinical trial participants to track their personal health data--and Apple and Google readying to provide the technology--mobile and wearables look set to make an impact on research. But does the public want to give researchers access to their data?
Trialbee informs people about upcoming trials by talking directly to patient groups on social media and through mobile apps.
The merger expands the range of medical imaging services BioClinica can offer while also moving it into new areas, notably clinical trial services and patient recruitment.
Patient-recruitment specialist Synexus has opened an administrative center in Wroclaw, Poland, designed to oversee its expansion throughout Eastern Europe.
Quintiles has kicked off a study to determine whether early genomic profiling of cancer patients can help inform physician decisions and match the right participant with the right study, a method the CRO said could speed up the development process of personalized drugs.